Small Cell Lung Cancer

During a Targeted Oncology™ Case-Based Roundtable™ event, Ticiana Leal, MD, discussed treatment options for recurrent extensive-stage small cell lung cancer, including topotecan, lurbinectedin, and platinum rechallenge.

In an interview with Targeted Oncology, Sagun Shrestha, MD, evaluated new developments and clinical trials for patients with extensive-stage small cell lung cancer.

Sagun Shrestha, MD, discusses how the addition of atezolizumab and durvalumab to treatment options for patients with extensive stage small cell lung cancer has impacted the field for the better.

A fast track designation has been granted by the FDA to quaratusugene ozeplasmid with atezolizumab for the treatment patients with extensive-stage small cell lung cancer.

The investigational agent, ABBV-011, is showing promise, according to results from a phase 1 clinical trial.

Further dose optimization is ongoing in the phase 1 study of BI 764532 following the read-out of positive results.

Lurbinectedin yielded a value of 6.52 nM on the key pharmacological efficacy variable IC50, according to a poster presented at the 2023 Annual Meeting of the American Association for Cancer Research

Qian Wang, MD, MPH, looks at the important metrics related to a patient’s smoking history that helps to determine their level of risk for developing small cell lung cancer.

Treatment with lurbinectedin is cost-effective as a second-line treatment for patients with metastatic small cell lung cancer who have had disease progression on or after platinum-based chemotherapy.

Ashish Saxena, MD, explains the outcomes of the addition of immune checkpoint blockade to standard chemotherapy for patients with metastatic small cell lung cancer.

Ashish Saxena, MD, PhD, discusses the standard-of-care regimens use to treat patients with small cell lung cancer at every stage.

In an interview, Ashish Saxena, MD, discussed the benefit of radiation for the treatment of small cell lung cancer, combining radiation with immune checkpoint blockade treatments, and the next steps for the space.

The effects of chemotherapy-induced myelosuppression for extensive-stage small cell lung cancer were assessed in a new study which used a real-world community oncology setting.

In an interview with Targeted Oncology, Nitika Sharma, MD, discussed frontline treatment options for small cell lung cancer and data supporting their use. Sharma also discussed ongoing clinical trials that may bring new therapies in the near future.

Qian Wang, MD, MPH, discusses the changing incidence of small cell lung cancer among patients globally and in the United States.

With little improvement in survival seen for patients with small cell lung cancer, investigators are now assessing novel agents that are shifting the treatment paradigm of extensive disease-small cell lung cancer.

Gene G. Finley, MD, provides advice to community oncologists who are treating patients with small cell lung cancer.

The upcoming THIO-102 trial will evaluate the safety and efficacy of THIO administered in sequence with pembrolizumab or atezolizumab across multiple tumor types.

JBI-802, which is being evaluated in a phase 1/2 trial, received an orphan drug designation from the FDA for the treatment of patients with small cell lung cancer and acute myeloid leukemia.

A phase 2 dose expansion cohort which received the investigational agent abequolixron plus docetaxel showed clinical responses in patients with non–small cell lung cancer and small cell lung cancer.

Patients with small cell lung cancer will receive diagnostic and post-progression tumor tissue profiling, plasma ctDNA biomarker profiling, standard of care therapy, and disease surveillance in the Sculptor study.

Kartik Konduri, MD discussed treatment options for extensive-stage small cell lung cancer during a live virtual event.

Real-world evidence from Florida Cancer Specialists & Research Institute shows that trilaciclib may reduce the chance of chemotherapy-induced myelosuppression events in patients with extensive-stage small cell lung cancer.

In season 3, episode 10 of Targeted Talks, Nitika Sharma, MD, discusses FDA-approved and promising novel therapies for the treatment of small cell lung cancer.

In a first-in-human trial, a peptide-drug conjugate showed tolerability and antitumor activity in patients with advanced solid tumors.